These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3578266)

  • 1. Spontaneous antithrombin in a patient with benign paraprotein.
    Gabriel DA; Carr ME; Cook L; Roberts HR
    Am J Hematol; 1987 May; 25(1):85-93. PubMed ID: 3578266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.
    Nawarawong W; Wyshock E; Meloni FJ; Weitz J; Schmaier AH
    Br J Haematol; 1991 Oct; 79(2):296-301. PubMed ID: 1958489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer.
    Liebman HA; Comenzo R; Allen ST; Dilorio JM
    Am J Hematol; 1991 Sep; 38(1):24-9. PubMed ID: 1897511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
    de Bosch NB; Mosesson MW; Ruiz-Sáez A; Echenagucia M; Rodriguez-Lemoin A
    Thromb Haemost; 2002 Aug; 88(2):253-8. PubMed ID: 12195697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of an antibody directed against exosite I of thrombin.
    Baglin TP; Langdown J; Frasson R; Huntington JA
    J Thromb Haemost; 2016 Jan; 14(1):137-42. PubMed ID: 26469093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
    Llobet D; Borrell M; Vila L; Vallvé C; Felices R; Fontcuberta J
    Haematologica; 2007 Feb; 92(2):e17-9. PubMed ID: 17405747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
    Colwell NS; Tollefsen DM; Blinder MA
    Br J Haematol; 1997 Apr; 97(1):219-26. PubMed ID: 9136969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis.
    Shigekiyo T; Kosaka M; Shintani Y; Azuma H; Iishi Y; Saito S
    Acta Haematol; 1989; 81(3):160-5. PubMed ID: 2496565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin.
    O'Kane MJ; Wisdom GB; Desai ZR; Archbold GP
    J Clin Pathol; 1994 Mar; 47(3):266-8. PubMed ID: 8163700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin Resistance Rescues Clotting Defect of Homozygous Prothrombin-Y510N Dysprothrombinemia.
    Lu Y; Villoutreix BO; Biswas I; Ding Q; Wang X; Rezaie AR
    Thromb Haemost; 2022 May; 122(5):679-691. PubMed ID: 34256393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
    Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
    J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired dysfibrinogenemia secondary to multiple myeloma.
    Kotlín R; Sobotková A; Riedel T; Salaj P; Suttnar J; Reicheltová Z; Májek P; Khaznadar T; Dyr JE
    Acta Haematol; 2008; 120(2):75-81. PubMed ID: 18841003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure.
    Elgue G; Sanchez J; Fatah K; Olsson P; Blombäck B
    Thromb Res; 1994 Jul; 75(2):203-12. PubMed ID: 7974394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional evaluation of an inherited abnormal fibrinogen: fibrinogen "Baltimore".
    Beck EA; Shainoff JR; Vogel A; Jackson DP
    J Clin Invest; 1971 Sep; 50(9):1874-84. PubMed ID: 5564395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma.
    Mischke R; Wolling H
    Haemostasis; 2000; 30(3):123-30. PubMed ID: 11014962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome.
    Kolev K; Léránt I; Skopál J; Kelemen A; Nagy Z; Machovich R
    Thromb Haemost; 2005 Jul; 94(1):82-7. PubMed ID: 16113788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma globulin inhibition of fibrin clot formation.
    Davey FR; Gordon GB; Boral LI; Gottlieb AJ
    Ann Clin Lab Sci; 1976; 6(1):72-7. PubMed ID: 1247286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.